Takeda wades through more Vyvanse declines, muses DTC model as US pricing uncertainty looms
30th July 2025 Uncategorised 0The Japanese drugmaker’s quarterly revenues took an 8.4% hit with continued Vyvanse-related generic erosion reaching a high and bringing down its U.S. sales.
More: Takeda wades through more Vyvanse declines, muses DTC model as US pricing uncertainty looms
Source: fierce